

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/06/30	2015/12/31	2015/06/30
<b>Balance Sheet</b>			
<b>Current assets</b>			
Total cash and cash equivalents	406,372	305,619	432,001
Total Current investments in debt instrument without active market	510,850	859,867	809,961
Notes receivable due from related parties, net	0	71	0
Accounts receivable, net	9,232	18,570	7,617
Other receivables, net	2,746	2,892	14,042
Total current tax assets	2,386	4,038	3,404
Total inventories	54,222	22,627	20,669
Total prepayments	45,467	21,576	15,748
Total other current assets	19,287	9,323	1,121
<b>Total current assets</b>	<b>1,050,562</b>	<b>1,244,583</b>	<b>1,304,563</b>
<b>Non-current assets</b>			
Total Non-current investments in debt instrument without active market	30,000	30,000	30,000
Total property, plant and equipment	274,969	199,876	190,422
Total intangible assets	1,100	580	1,191
Deferred tax assets	39,540	40,173	39,926
Total other non-current assets	57,111	3,174	3,455
<b>Total non-current assets</b>	<b>402,720</b>	<b>273,803</b>	<b>264,994</b>
<b>Total assets</b>	<b>1,453,282</b>	<b>1,518,386</b>	<b>1,569,557</b>
<b>Current liabilities</b>			
Total accounts payable	46,249	19,619	15,760
Total accounts payable to related parties	0	40	10
Total other payables	39,786	30,362	21,718
Total other current liabilities	14,152	11,618	9,153
<b>Total current liabilities</b>	<b>100,187</b>	<b>61,639</b>	<b>46,641</b>
<b>Non-current liabilities</b>			
Total deferred tax liabilities	362	796	0
Total other non-current liabilities	1,714	1,737	3,034
<b>Total non-current liabilities</b>	<b>2,076</b>	<b>2,533</b>	<b>3,034</b>
<b>Total liabilities</b>	<b>102,263</b>	<b>64,172</b>	<b>49,675</b>
<b>Share capital</b>			
Ordinary share	1,118,180	1,115,990	1,110,730
Advance receipts for share capital	2,349	2,211	5,548
<b>Total share capital</b>	<b>1,120,529</b>	<b>1,118,201</b>	<b>1,116,278</b>
<b>Capital surplus</b>			
Total capital surplus, additional paid-in capital	618,481	614,631	606,189
Capital surplus, treasury share transactions	2,812	2,812	2,812
Capital surplus, employee share options	7,070	3,876	6,994
<b>Total capital surplus</b>	<b>628,363</b>	<b>621,319</b>	<b>615,995</b>
<b>Retained earnings</b>			
Total unappropriated retained earnings (accumulated deficit)	-310,262	-197,695	-177,985
<b>Total retained earnings</b>	<b>-310,262</b>	<b>-197,695</b>	<b>-177,985</b>
<b>Other equity interest</b>			
Total revaluation surplus	0	0	0
Total other equity, others	0	0	0
<b>Total other equity interest</b>	<b>0</b>	<b>0</b>	<b>0</b>
Treasury shares	-87,611	-87,611	-34,406
Equity attributable to former owner of business combination under common control	0	0	0
Equity attributable to non-controlling interest before business combination under common control	0	0	0
<b>Total equity</b>	<b>1,351,019</b>	<b>1,454,214</b>	<b>1,519,882</b>
<b>Total liabilities and equity</b>	<b>1,453,282</b>	<b>1,518,386</b>	<b>1,569,557</b>
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	120,500	116,000	266,500
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	836,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/2nd	2015/2nd	2016/01/01To2016/06/30	2015/01/01To2015/06/30
<b>Income Statement</b>				
Total operating revenue	30,060	7,764	40,029	19,749
Total operating costs	39,351	26,230	70,008	42,023
Gross profit (loss) from operations	-9,291	-18,466	-29,979	-22,274
Gross profit (loss) from operations	-9,291	-18,466	-29,979	-22,274
Operating expenses				
Total selling expenses	2,375	1,215	4,460	1,802
Total administrative expenses	7,733	11,053	14,811	17,671
Total research and development expenses	47,910	31,080	88,986	63,510
Total operating expenses	58,018	43,348	108,257	82,983
Net operating income (loss)	-67,309	-61,814	-138,236	-105,257
Non-operating income and expenses				
Total other income	14,675	10,154	28,046	20,926
Other gains and losses, net	101	-1,111	-2,178	-5,421
Total non-operating income and expenses	14,776	9,043	25,868	15,505
Profit (loss) from continuing operations before tax	-52,533	-52,771	-112,368	-89,752
Total tax expense (income)	134	211	199	298
Profit (loss) from continuing operations	-52,667	-52,982	-112,567	-90,050
Profit (loss)	-52,667	-52,982	-112,567	-90,050
Total comprehensive income	-52,667	-52,982	-112,567	-90,050
Basic earnings per share				
Total basic earnings per share	-0.48	-0.48	-1.03	-0.81

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2016/01/01To2016/06/30	2015/01/01To2015/06/30
<b>Statements of Cash Flows</b>		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-112,368	-89,752
Profit (loss) before tax	-112,368	-89,752
Depreciation expense	19,329	16,675
Amortization expense	447	671
Provision (reversal of provision) for bad debt expense	0	9
Interest income	-4,753	-7,712
Share-based payments	5,040	591
Impairment loss on non-financial assets	55	74
Other adjustments to reconcile profit (loss)	0	0
Total adjustments to reconcile profit (loss)	20,118	10,308
Decrease (increase) in notes receivable	71	0
Decrease (increase) in accounts receivable	9,338	32,527
Decrease (increase) in accounts receivable due from related parties	0	4,927
Decrease (increase) in other receivable	-186	-5,842
Decrease (increase) in inventories	-31,650	-5,778
Decrease (increase) in prepayments	-23,891	-3,181
Decrease (increase) in other current assets	-1,256	-219
Total changes in operating assets	-47,574	22,434
Increase (decrease) in accounts payable	26,630	4,327
Increase (decrease) in accounts payable to related parties	-40	-13
Increase (decrease) in other payable	-3,082	-6,160
Increase (decrease) in other current liabilities	2,534	-6,260
Increase (decrease) in net defined benefit liability	-23	68
Total changes in operating liabilities	26,019	-8,038
Total changes in operating assets and liabilities	-21,555	14,396
Total adjustments	-1,437	24,704
Cash inflow (outflow) generated from operations	-113,805	-65,048
Income taxes refund (paid)	1,652	-675
Net cash flows from (used in) operating activities	-112,153	-65,723
Cash flows from (used in) investing activities		
Acquisition of investments in debt instrument without active market	-213,121	-839,714
Proceeds from disposal of investments in debt instrument without active market	562,138	1,155,502
Increase in prepayments for investments	-20,000	0
Acquisition of property, plant and equipment	-81,774	-38,537
Increase in refundable deposits	439	-135
Acquisition of intangible assets	-287	0
Increase in other financial assets	-8,708	0
Increase in prepayments for business facilities	-35,198	-351
Interest received	5,085	7,575
Net cash flows from (used in) investing activities	208,574	284,340
Cash flows from (used in) financing activities		
Proceeds from issuing shares	0	0
Exercise of employee share options	4,332	6,641
Payments to acquire treasury shares	0	-32,111
Net cash flows from (used in) financing activities	4,332	-25,470
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	100,753	193,147
Cash and cash equivalents at beginning of period	305,619	238,854
Cash and cash equivalents at end of period	406,372	432,001
Cash and cash equivalents reported in the statement of financial position	406,372	432,001
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

